Skip to Content

Bayer AG ADR BAYRY Stock Quote

| Rating as of

Morningstar‘s Stock Analysis BAYRY

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Bayer’s Core Business Lines in Healthcare and Crop Sciences Look Well Positioned Over the Long Term

Damien Conover, CFA Sector Director

Business Strategy and Outlook

| Damien Conover, CFA |

Largely on the basis of the strong competitive advantages of the healthcare group and to a lesser extent the crop science business, we believe Bayer has created a wide economic moat. Also, the past divestiture of no-moat material science group Covestro leaves the company in a stronger competitive position.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BAYRY

Company Profile BAYRY

Business Description

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins. The firm has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

Kaiser-Wilhelm-Allee 1
Leverkusen, 51368, Germany
T +49 214301
Industry Drug Manufacturers - General
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 100,753

Related News BAYRY